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Purpose: The aim of this study was to assess the correlation of hemoglobin A1c (HbA1c) levels with choroidal
thickness in patients with type 2 diabetesmellitus (DM) using spectral domain optical coherence tomography
(SD-OCT).
Methods: In this prospective case series, 180 eyes from 90 patients with type 2 DM were classified into
three study groups based on HbA1c values: group 1 included patients with good glycemic control (HbA1c
≤ 7%), group 2 included patients with moderate glycemic control (HbA1c between 7% and 8%), and group
3 included patients with poor glycemic control (HbA1c ≥ 8%). Additionally, 50 eyes from 25 non-diabetic
subjects were enrolled to group 4 as a control group. Sub-foveal, nasal, and temporal choroidal thickness
were measured and compared.
Results: Mean central, nasal, and temporal choroidal thicknesses in diabetic patients (247.80, 238.63, and
239.30 𝜇m) were significantly less than non-diabetic healthy subjects (277.56, 262.92, and 266.32 𝜇m).
Additionally, mean central, nasal, and temporal choroidal thickness values in group 4 (277.56, 262.92, and
266.32 𝜇m) were significantly greater than the corresponding values in group 2 (248.34, 237.55, and 236.45
𝜇m) and group 3 (239.81, 234.62, and 233.94 𝜇m), but was not significantly different from corresponding
values in group 1 (259.46, 246.12, and 251.00 𝜇m).
Conclusion: HbA1c values have a significant correlation with choroidal thickness in diabetic patients, and
better glycemic control with HbA1c ≤ 7% may prevent choroidal thinning.
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INTRODUCTION
Diabetic retinopathy (DR) is one of the major
causes of visual impairment worldwide.[1] The clin-
ical features and pathogenesis of DR are primar-
ily related to retinal vascular changes; however,
choroidal vascular damage may have an important
role.[2] Delayed filling of the choroidal vessels
using indocyanine green angiography has been
reported in eyes with DR.[3–5] Moreover, reduction
in the choroidal blood flow and choroidal volume
has been demonstrated in eyes with both non-
proliferative and proliferative DR using Doppler
flowmetry.[6] Choroidal vascular changes, including
choroidal aneurysms, choroidal vessel narrowing
and tortuosity, choroidal neovascularization, and
choroidal non-perfusion may occur in eyes with
DR.[7, 8]
Optical coherence tomography (OCT) is a non-
invasive method that allows high resolution in
vivo imaging of the posterior segment of the
eye.[9] Nowadays, improvement of the enhanced
depth imaging (EDI) software permits highly reliable
measurement of the choroidal thickness.[10, 11]
Hemoglobin A1c (HbA1c) is one of the stan-
dard tools for the assessment of glycemic control
and its optimum value is 5.6–7% in patients with
diabetes.[12] A previous study reported that at least
1% reduction in HbA1c can lead to significant reduc-
tion of the serious complications of DM, includ-
ing death, myocardial infarction, and microcellular
damage. [13]
The aim of this study was to evaluate the corre-
lation of HbA1c values with choroidal thickness in
diabetic patients using EDI-OCT.
METHODS
Patients with type 2 diabetes mellitus (DM) with
no evidence of DR or with mild non-proliferative
diabetic retinopathy (NPDR) were enrolled in this
cross-sectional study. The disease severity was
determined based on the clinical findings and
using the International Clinical Disease Sever-
ity Scale for DR.[14] In eyes with ”no diabetic
retinopathy”, as the name implies, there were no
diabetic changes in the fundus examination, and
eyes with ”mild NPDR” were characterized only
by the presence of a few microaneurysms. All
fundus examinations were performed by a single
vitreoretinal specialist.
The exclusion criteria were the presence of DR
more than mild NPDR, diabetic macular edema
(DME), any other ocular disorders, history of ocu-
lar surgery, including laser photocoagulation or
intraocular anti-vascular endothelial growth fac-
tor (anti-VEGF) injection, myopia more than −3
diopters, hyperopia more than +3 diopters, and
patients with a history of hypertension or any other
systemic diseases besides DM.
The current study was approved by the Ethics
Committee of our institute and was performed in
agreement with the ethical principles of the Decla-
ration of Helsinki. Informed consent was obtained
from every enrolled subject.
EDI-OCT using Heidelberg spectral domain OCT
(SD-OCT; Spectralis, Wavelength: Heidelberg Engi-
neering Co., Heidelberg, Germany) was performed
without pupillary dilation on the same day as blood
sampling. Complete ophthalmic examinationswere
performed one or two days before EDI-OCT imag-
ing. All OCT scans were performed by the same
experienced operator between 11 and 11:45 am to
avoid potential choroidal thickness changes with
circadian rhythm.
Central sub-foveal choroidal thickness was mea-
sured using the caliper that is present (Spec-
tralis software version 5.3; Heidelberg Engineering)
from the hyper-reflective line corresponding to
the Bruch’s membrane under the retinal pigment
epithelium (RPE) to the interface of the choroid
and sclera, in the central horizontal B-scan passing
directly through the foveal center. Then, the nasal
and temporal choroidal thickness were measured
500 𝜇m nasal and temporal to the central sub-
foveal point. Choroidal thickness measurements
were performed by a single vitreoretinal spe-
cialist who was masked to the identity of the
patients and the study groups. Twenty-five patients
were selected randomly from different groups and
their choroidal thickness was measured again.
Intraclass correlation coefficient for intra-observer
reproducibility was 0.91. Patients with inadequate
image quality in whom the interface of the choroid
and sclera was not recognizable were excluded.
All subjects were enrolled into three study
groups based on HbA1c values:
Group 1 included patients with good glycemic
control (HbA1c ≤ 7%), group 2 included patients
with moderate glycemic control (HbA1c between
7% and 8%), and group 3 included patients with
poor glycemic control (HbA1c ≥ 8%). Healthy
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non-diabetic subjects were enrolled to group 4 as
a control group. Sub-foveal, nasal, and temporal
choroidal thickness were measured and compared
in the eyes of all study groups.
Statistical Analysis
Data were analyzed using SPSS version 24 (IBM
Corp, Armonk, NY, USA). Mean ± SD was reported
for quantitative variables. Percentage was reported
for qualitative variables. The Kolmogorov-Smirnov
test was used to evaluate normal distribution
in quantitative variables. Analysis of variance
(ANOVA) or an equivalent non-parametric test
(Kruskal-Wallis H test) was used to compare quanti-
tative variables between the four groups. Post hoc
test (Tukey test) was used if the ANOVA was signif-
icant. A correlation test (Pearson coefficient when
the variables had normal distribution or Spearman
coefficient when the distribution of variables was
not normal) was used to evaluate the correlation
of choroidal thickness and quantitative variables,
such as fasting blood sugar (FBS), duration of
diabetes, etc. An independent sample’s t-test or
equivalent non-parametric test (Mann-Whitney U
test) was used to compare between two groups,
such as the diabetic and non-diabetic ones. The
paired sample t-test was used to compare variables
within each groups such as the comparison of
central choroidal thickness between right and left
eyes. 𝑃 -value < 0.05 was considered significant.
RESULTS
A total of 180 eyes from 90 diabetic patients
and 50 eyes from 25 non-diabetic patients were
enrolled in this study. Group 1 included 48 eyes
from 24 diabetic patients with good glycemic
control (HbA1c ≤ 7%), group 2 included 58 eyes
from 29 diabetic patients with moderate glycemic
control (HbA1c between 7% and 8%), and group
3 included 74 eyes from 37 diabetic patients with
poor glycemic control (HbA1c ≥ 8%). Additionally,
group 4 included 50 eyes from 25 non-diabetic
subjects as the control group.
The mean age and duration of DM was similar
among all study groups [Table 1]. There was no sig-
nificant difference between mean central choroidal
thickness of the right (247.80 ± 39.74 𝜇m) and left
eyes (248.12 ± 37.40 𝜇m) of diabetic patients in all
study groups (𝑃 = 0.849).
Overall, the mean central, nasal, and temporal
choroidal thickness in diabetic patients (180 eyes)
were significantly lower than those in the non-
diabetic healthy subjects (50 eyes) [Table 2]; how-
ever, the mean central macular thickness in the
diabetic eyes (251.51± 26.22 𝜇m) and non-diabetic
eyes (246.24 ± 22.46 𝜇m) had no significant
difference (𝑃 = 0.72).
Choroidal thickness in diabetic patients in group
1 had no significant difference with non-diabetic
patients (𝑃 = 0.093, 𝑃 = 0.379, and 𝑃 = 0.450 for
central, nasal, and temporal points, respectively)
and diabetic patients in group 2 (𝑃 = 0.276, 𝑃
= 0.830, and 𝑃 = 0.465 for central, nasal, and
temporal points, respectively) [Table 3]. However,
choroidal thickness in diabetic patients in group
1 was significantly greater than patients in group
3 (𝑃 = 0.016, 𝑃 = 0.042, and 𝑃 = 0.031 for
central, nasal, and temporal points, respectively).
Choroidal thicknesses in diabetic patients in group
2 was significantly more than patients in group
3 (𝑃 = 0.003, 𝑃 = 0.026, and 𝑃 = 0.032 for
central, nasal, and temporal points, respectively).
Choroidal thicknesses was significantly greater in
non-diabetic eyes than diabetic eyes in group 2 (𝑃
= 0.043,𝑃 = 0.025 and𝑃 = 0.0.016 for central, nasal,
and temporal points, respectively) and group 3 (𝑃
= 0.001, 𝑃 = 0.018 and 𝑃 = 0.004 for central, nasal,
and temporal points, respectively).
The mean central choroidal thickness in diabetic
patients had no significant correlation with FBS (r
= −0.063 and 𝑃 = 0.685), duration of diabetes (r =
−0.092 and 𝑃 = 0.390), and age (𝑟 = 0.122 and 𝑃 =
0.253).
Since patients with DMEwere excluded from this
study, the mean central macular thickness was not
different among all study groups.
DISCUSSION
In this study, we found that the choroidal thick-
ness in non-diabetic patients was significantly
greater than in diabetic patients. Moreover, this
study showed that the choroidal thickness in non-
diabetic patients was similar to that in diabetic
patients with good glycemic control (HbA1c ≤ 7%)
and was significantly greater than that in diabetic
patients with moderate or poor glycemic control
(HbA1c > 7%).
Lee and co-workers evaluated the choroidal
thickness in diabetic patients using SD-OCT.[11]
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Table 1. Demographic data of subjects in all study groups
Group1 Group2 Group3 Group4 P-value
Number of cases (patients/eyes) 24/48 29/58 37/74 25/50
Age 56.20 ± 8.13 59.02 ± 6.43 57.45 ± 7.44 59.10 ± 6.43 0.723
Sex (male/female) 13/11 16/13 17/20 13/12 0.682
Duration of DM (years) 6.12 ± 4.51 6.81 ± 5.20 7.10 ± 4.26 0.249
Mean HbA1c 6.12 ± 0.53 7.55 ± 0.39 10.21 ± 1.16 <0.001
DM, diabetes mellitus; HbA1c, hemoglobin A1c
Table 2. Comparison of choroidal and central macular thickness between diabetic and non-diabetic subjects
Diabetic cases Non-diabetic cases P-value
Central choroidal thickness 247.80 ± 39.74 277.56 ± 34.15 0.001
Choroidal thickness at nasal point 238.63 ± 37.00 262.92 ± 34.44 0.004
Choroidal thickness at temporal point 239.30 ± 37.32 266.32 ± 32.47 0.001
Central macular thickness 251.51 ± 26.22 246.24 ± 22.46 0.72
They examined 203 eyes of 203 diabetic patients
and 48 eyes of 48 non-diabetic controls and
showed that the sub-foveal choroidal thickness
was less in the eyes with NPDR or PDR than that in
the healthy non-diabetic eyes; however, there was
no significant difference between the diabetic eyes
with no DR and the normal control eyes. Sudhalkar
et al assessed choroidal thickness changes in
different types of DR.[15] They showed that diabetic
patients with or without DR had a significantly
thinner choroid compared to non-diabetic control
group. Moreover, they found that patients with
PDR had a thinner sub-foveal choroid than patients
with NPDR. The authors concluded that choroidal
thinning continued with increasing stages of DR.
In the current study, we showed that choroidal
thickness in diabetic eyes is less than that in non-
diabetic control eyes. This finding is in agreement
with Lee et al,[11] Sudhalkar et al,[15] as well as
some other previous studies reporting choroidal
thinning in diabetic patients compared to non-
diabetic patients.[16, 17] However, some other stud-
ies reported no significant difference in choroidal
thickness between the diabetic and non-diabetic
eyes.[18]
A previous study showed that abnormalities
in the choriocapillaris and reduction of choroidal
blood flow occurred in the early stages of DR,[19]
which may lead to choroidal hypoxia and ischemia
and finally choroidal thinning. Yazici and co-
workers compared the choroidal thickness in dia-
betic patients with and without polyneuropathy
and healthy control subjects.[20] They reported
that the central choroid is thicker in diabetic
patients compared to normal subjects and also
showed that there was additional choroidal thick-
ening in diabetic patients with polyneuropathy.
They concluded that choroidal thickening may
be related to autonomic dysregulation secondary
to diabetic neuropathy. Kocasarac et al com-
pared the choroidal thickness between diabetic
patients with nephropathy and diabetic patients
without nephropathy and found that the choroid
is thinner in patients with diabetic nephropathy.[21]
Additionally, Faries et al reported that in diabetic
patients with microalbuminuria, central choroidal
thickness is less than diabetic patients without
microalbuminuria.[22] Microalbuminuria is an indi-
cator of generalized vascular dysfunction;[21] there-
fore, choroidal thinning in these patients may be a
sign of choroidal vascular damage and dysfunction.
Sahinoglu-Keskek et al classified 122 eyes of 122
diabetic patients into three study groups including
diabetic patients without DR, diabetic patients with
DR and no macular edema, and diabetic patients
with DR and macular edema.[23] They reported
that the sub-foveal choroid in patients with no
DR was significantly thicker than that in patients
with DR and without macular edema. Moreover,
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Table 3. The mean choroidal and central macular thickness in all study groups






Group1 259.46 ± 39.73 246.12 ± 43.55 251.00 ± 42.91 258.29 ± 31.29
Group2 248.34 ± 33.72 237.55 ± 31.67 236.45 ± 33.95 254.17 ± 17.84
Group3 239.81 ± 43.08 234.62 ± 36.58 233.94 ± 35.27 245.03 ± 27.34
Group4 277.56 ± 34.16 262.92 ± 34.45 266.32 ± 32.48 246.24 ± 8.46
they reported that no significant differences in
HbA1c levels were detected among the three
study groups and concluded that there was no
correlation between sub-foveal choroidal thickness
andHbA1c values. Unlike Sahinoghlu-Keskek et al’s
study, we classified diabetic patients with the same
DR severity based on HbA1c values and compared
the choroidal thickness among them and found
that the choroidal thickness in the healthy control
group was nearly equal to that in patients with
good glycemic control (HbA1c ≤ 7%) and was
significantly more than the choroidal thickness in
diabetic patients with moderate or poor glycemic
control (HbA1c > 7%). Permanent high blood sugar
levels in diabetic patients with inadequate treat-
ment may lead to choroidal vascular damage and
cause choroidal thinning in patient with DR.[18]
Therefore, in patients with uncontrolled DM and
high levels of HbA1c, the choroid is expected
to be thinner. Unsal et al reported a weak to
moderate negative correlation between the sub-
foveal choroidal thickness andHbA1c values, which
is compatible with our results.[24]
Poorly controlled HbA1c is associated with more
severe stages of DR;[25] this may be due to the
lower choroidal blood flow and choroidal hypoxia
in the higher concentrations of blood sugar that
ultimately may lead to choroidal thinning. Diabetic
choroidopathy may play a major role in the patho-
genesis of DR because the outer retinal layers
are dependent on the choroid for nutrition and
oxygenation.[7]
In the current study, we found that there was
no significant correlation between the duration of
diabetes and choroidal thickness. This is compati-
ble with the studies of Sahinoghlu-Keskek et al and
Shen et al.[23, 26]
We are aware of some of the limitations of our
study. First, we had no axial length data; how-
ever, the patients with high refractive errors were
excluded. The possibility of measurement errors
due to manual measurement and measurement by
a single observer constitute other limitations.
In conclusion, we showed that the choroidal
thickness in normal control subjects was almost
equal to diabetic patients with good glycemic
control (HbA1c ≤ 7%) and was significantly greater
than choroidal thickness in diabetic patients with
moderate or poor glycemic control (HbA1c > 7%).
Therefore, better diabetic control with HbA1c ≤
7% may prevent choroidal vascular damage and
choroidal thinning and finally prevent the develop-
ment of DR. However, future studies with larger
sample size are required to establish the corre-
lation of choroidal thickness with HbA1c and to
determine the optimal cutoff value of HbA1c that
affects the choroidal vascular system.
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